Healthcare · Medical - Equipment & Services
Price
$0.73
Market Cap
$286.6M
Employees
388
Beta
1.38
Avg Volume
2,988,227
CEO
Michael Egholm
Business Description
Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments. Its proteomics and genomics include instruments, consumables, and assays for clinical and diagnostic uses. The company also provides SomaScan platform that enables researchers to measure proteins simultaneously and provides deep insights into biological processes and disease mechanisms; CyTOF technology platform that uses metal-tagged antibodies and time-of-flight mass spectrometry to eliminate signal interference and expand multiplexing capabilities; Hyperion, a spatial biology platform, which unlocks deeper insights into tissue organization by preserving spatial context while enabling high-dimensional molecular and proteomic analysis; and Biomark X9 system that redefines high-throughput genomics for quantitative polymerase chain reaction applications. The company sells its instruments and consumables for research use only to academic research institutions, translational research and medicine centers, cancer centers, and clinical research laboratories, as well as biopharmaceutical, biotechnology, and plant and animal research companies. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in November 2001. Standard BioTools Inc. was incorporated in 1999 and is headquartered in Boston, Massachusetts.
Business History
Price Overview
Last updated: Jun 27, 2026 8:56am (just now)$0.73
-0.01 (-0.80%)
Day Range
$0.71 – $0.77
52-Week Range
$0.70 – $1.72
50-Day MA
$0.96
200-Day MA
$1.18
Volume
35,129,140.00
Analyst Price Targets
Low
$3.25
Consensus
$3.25
High
$3.25
(1 analysts)
Share Structure
Outstanding
390,368,000.00
Float
42,654,742.00
Free Float
10.9%
Very low free float
— 10.9% of shares trade freely, ~89.1% held by insiders/institutions
Thinly traded — expect wider bid-ask spreads and sharp price swings on modest volume. Institutional investors may avoid due to liquidity constraints.
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALCStock Price / EPS (Diluted)
-3.67
Stock Price: $0.73
EPS (Diluted): -0.20
EPS (Diluted): -0.20
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
1.15
Stock Price: $0.73
Total Equity: $424.29M
Shares: 381,623,000
Total Equity: $424.29M
Shares: 381,623,000
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
-0.62
Market Cap: $286.61M
Total Debt: $5.79M
Cash: $118.21M
EBITDA: -$89.69M
Total Debt: $5.79M
Cash: $118.21M
EBITDA: -$89.69M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$401.1M
Market Cap: $286.61M
Total Debt: $5.79M
Cash: $118.21M
Total Debt: $5.79M
Cash: $118.21M
P/S Ratio (Price per dollar of revenue)
APIStock Price / Revenue Per Share
5.72
Stock Price: $0.73
Revenue: $85.33M
Shares: 381,623,000
Revenue: $85.33M
Shares: 381,623,000
EV/Sales (Total value vs revenue — works when P/E can't)
API4.70
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
49.9%
Gross Profit: $42.54M
Revenue: $85.33M
Revenue: $85.33M
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
-109.3%
Operating Income: -$93.31M
Revenue: $85.33M
Revenue: $85.33M
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
-87.8%
Net Income: -$74.90M
Revenue: $85.33M
Revenue: $85.33M
ROE (Profit from shareholder equity)
APINet Income / Total Equity
-20.8%
Net Income: -$74.90M
Total Equity: $424.29M
Total Equity: $424.29M
ROIC (Profit from all invested capital)
APINOPAT / Invested Capital
-7.4%
Operating Income: -$93.31M
Tax Rate: 39.2%
Equity: $424.29M
Total Debt: $5.79M
Cash: $118.21M
Tax Rate: 39.2%
Equity: $424.29M
Total Debt: $5.79M
Cash: $118.21M
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
4.19
Current Assets: $454.26M
Current Liabilities: $108.31M
Current Liabilities: $108.31M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
0.01
Short-Term Debt: $5.49M
Long-Term Debt: $299,000
Total Debt: $5.79M
Total Equity: $424.29M
Long-Term Debt: $299,000
Total Debt: $5.79M
Total Equity: $424.29M
Rev/Share (Top-line per share)
CALCRevenue / Shares Outstanding
$0.22
Revenue: $85.33M
Shares: 381,623,000
Shares: 381,623,000
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$1.11
Total Equity: $424.29M
Shares: 381,623,000
Shares: 381,623,000
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$-0.22
Operating CF: -$74.35M
CapEx: -$8.30M
Shares: 381,623,000
CapEx: -$8.30M
Shares: 381,623,000
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $0.73
Stock Price: $0.73
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$74.90M
Net Income: -$74.90M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares LAB against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jun 27, 2026 12:48am (8h ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $130.6M | $97.9M | $106.3M | $174.4M | $85.3M |
| Cost of Revenue | $61.2M | $60.9M | $55.9M | $90.2M | $42.8M |
| Gross Profit | $69.4M | $37.1M | $50.5M | $84.3M | $42.5M |
| Operating Expenses | $136.8M | $153.3M | $127.1M | $259.5M | $135.8M |
| Operating Income | -$67.5M | -$116.2M | -$76.6M | -$175.2M | -$93.3M |
| Net Income | -$59.2M | -$190.1M | -$74.7M | -$138.9M | -$74.9M |
| EBITDA | -$44.3M | -$173.6M | -$54.5M | -$118.1M | -$89.7M |
| EPS | $-0.78 | $-2.43 | $-0.94 | $-0.52 | $-0.20 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 27, 2026 12:48am (8h ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $28.5M | $81.3M | $51.7M | $166.7M | $118.2M |
| Total Current Assets | $72.1M | $208.8M | $158.2M | $375.9M | $454.3M |
| Total Assets | $275.2M | $390.3M | $323.1M | $612.3M | $567.8M |
| Current Liabilities | $49.6M | $43.4M | $109.3M | $65.9M | $108.3M |
| Long-Term Debt | $64.2M | $62.8M | $4.0M | $299,000 | $299,000 |
| Total Liabilities | $180.6M | $471.8M | $471.1M | $140.6M | $143.5M |
| Total Equity | $94.6M | -$81.5M | -$148.1M | $471.7M | $424.3M |
| Retained Earnings | -$736.0M | -$926.1M | -$1.0B | -$1.2B | -$1.3B |
Cash Flow (Annual)
Last updated: Jun 27, 2026 12:48am (8h ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$44.1M | -$89.4M | -$43.3M | -$143.5M | -$74.4M |
| Capital Expenditure | -$13.3M | -$3.8M | -$2.8M | -$8.4M | -$8.3M |
| Free Cash Flow | -$57.3M | -$93.2M | -$46.1M | -$151.8M | -$82.7M |
| Acquisitions (net) | $0 | $0 | $0 | $278.6M | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | -$1.8M | $-774,000 | -$5.4M | -$40.9M | $0 |
| Net Change in Cash | -$40.1M | $52.9M | -$29.8M | $116.3M | -$48.2M |
Analyst Estimates (Annual)
Last updated: Jun 27, 2026 12:48am (8h ago)| Metric | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|
| Revenue |
$82.5M $82.0M – $83.0M
|
$84.1M $83.6M – $84.6M
|
$88.0M $86.9M – $89.2M
|
$89.4M $88.9M – $89.9M
|
| EBITDA |
-$58.2M -$58.6M – -$57.9M
|
-$59.3M -$59.7M – -$59.0M
|
-$62.1M -$63.0M – -$61.3M
|
-$63.1M -$63.5M – -$62.7M
|
| Net Income |
-$12.6M -$12.7M – -$12.5M
|
-$33.1M -$33.3M – -$32.8M
|
-$29.8M -$30.0M – -$29.6M
|
-$57.2M -$57.7M – -$56.8M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 27, 2026 12:48am (8h ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | -25.0% | +8.6% | +64.0% | -51.1% |
| Gross Profit Growth | -46.6% | +36.2% | +67.0% | -49.5% |
| Operating Income Growth | -72.3% | +34.1% | -128.8% | +46.8% |
| Net Income Growth | -220.9% | +60.7% | -86.0% | +46.1% |
| EBITDA Growth | -292.1% | +68.6% | -116.9% | +24.1% |
Insider Trading (Recent)
Type codes
PPurchase
SSale
AAward / grant
MOption exercise
FIn-kind (tax)
CConversion
GGift
DReturn to issuer
All SEC Form 4 codes
Open market
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
Compensation (Rule 16b-3)
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
Derivatives
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
Other exempt
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
Other
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-06-18 | Carey Thomas D. | A-Award | 99,116.00 | $0.00 | $0 |
| 2026-06-18 | Carey Thomas D. | A-Award | 263,884.00 | $0.83 | $218,945 |
| 2026-06-20 | Mackay Sean | A-Award | 500,000.00 | $0.00 | $0 |
| 2026-06-18 | Witney Frank | A-Award | 99,116.00 | $0.00 | $0 |
| 2026-06-18 | Witney Frank | A-Award | 175,923.00 | $0.83 | $145,963 |
| 2026-06-18 | Casdin Eli | A-Award | 99,116.00 | $0.00 | $0 |
| 2026-06-18 | Casdin Eli | A-Award | 175,923.00 | $0.83 | $145,963 |
| 2026-06-18 | Cox Troy | A-Award | 99,116.00 | $0.00 | $0 |
| 2026-06-18 | Cox Troy | A-Award | 175,923.00 | $0.83 | $145,963 |
| 2026-06-18 | ELOI FENEL M | A-Award | 99,116.00 | $0.00 | $0 |
| 2026-06-18 | ELOI FENEL M | A-Award | 175,923.00 | $0.83 | $145,963 |
| 2026-06-18 | HIBBS KATHY L | A-Award | 99,116.00 | $0.00 | $0 |
| 2026-06-18 | HIBBS KATHY L | A-Award | 175,923.00 | $0.83 | $145,963 |
| 2026-05-20 | Kim Hanjoon Alex | F-InKind | 18,871.00 | $1.00 | $18,871 |
| 2026-05-20 | Mackay Sean | F-InKind | 25,729.00 | $1.00 | $25,729 |
| 2026-05-20 | Egholm Michael | F-InKind | 97,626.00 | $1.00 | $97,626 |
| 2026-04-06 | Egholm Michael | M-Exempt | 196,513.00 | $0.00 | $0 |
| 2026-04-06 | Egholm Michael | F-InKind | 95,014.00 | $0.91 | $86,273 |
| 2026-03-20 | Egholm Michael | A-Award | 1,042,373.00 | $0.00 | $0 |
| 2026-03-20 | Egholm Michael | A-Award | 2,345,340.00 | $0.98 | $2.3M |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for LAB — it's generated by the pipeline (
market-narrative step).
No community reviews yet for LAB.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.352 · d1100787 · 2026-06-26 11:39:30